slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 89,341-89,370
Pages 3,225
Rows per page 30
Component
89,341-89,370 of 96,741
30
Includes waterfall plot and spider plot (longitudinal response). Data cut-off Sep 30, 2023.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
40
Includes histological images of tumor/stroma and a longitudinal bioluminescence imaging study in mice.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
46
Includes a schematic diagram of the bispecific molecule on the left.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
47
The chart shows a clear performance advantage for the blue line (TCER®) over the grey lines.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
50
The slide uses a horizontal arrow-based process flow to categorize programs by development stage (Clinical vs Preclinical).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
51
Includes ISH images, a prevalence table, and a dot plot comparing peptide density.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
70
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
73
Data cut-off Sep 30, 2023. N=21 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
06
Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
20
Includes a disclaimer about cross-trial comparison limitations.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
38
The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
46
Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
08
The slide uses a schematic diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
10
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of NXC-201.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
13
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
19
The slide uses a grouped bar chart format to highlight clinical superiority. Includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
21
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
41
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
38
The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
41
Slide contains three distinct charts comparing IMX-110 against standard of care in mouse models.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
42
Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
07
Invitae | Results Presentation Deck | 27 slidesInvitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · NeedLoop · Why Now1 hit
22
Includes a table of liquidity metrics and a bar chart showing bond maturity distribution by year.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations 1 hit